Market Outlook

Peripheral arterial disease (PAD) is a complex manifestation of underlying atherosclerotic disease and is severely undertreated. The failure of therapies to improve walking distance or reduce amputation highlights the need for novel agents capable of reducing, preventing, or reversing the progression of PAD. We discuss how current therapies are differentiated based on their key attributes and measure the impact of these attributes on cardiologists’ prescribing behavior. We also discuss the most important unmet needs in the treatment of PAD and consider which emerging therapies, if any, can capitalize on these opportunities. Our conjoint analysis reveals the key trade-offs that surveyed physicians are willing to make for these attributes when considering new treatment options for PAD.

QUESTIONS ANSWERED

  • Which drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • Which PAD therapies are perceived by U.S. and European cardiologists as performing best on key treatment drivers and goals?
  • What are the major areas of opportunity for drug developers in PAD treatment and their likelihood of being fulfilled in the near future?
  • Based on the conjoint analysis and TPP simulation, what trade-offs across different clinical attributes and price are acceptable to U.S. and European cardiologists for a hypothetical new PAD drug?

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 30 European cardiologists fielded in June 2019.

Key drugs covered: Aspirin, clopidogrel, statins, Xarelto, Repatha, Praluent, and vasoactive agents.

Key metrics included Target Product Profile (TPP) simulator based on conjoint analysis methodology. Stated versus derived importance of product attributes on prescribing behavior. Assessment of current drug performance against treatment drivers and goals. Physician perceptions of unmet needs in the indication and related indications. Analysis of remaining drug development opportunities.

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Table of contents

  • Peripheral Arterial Disease - Unmet Need - Detailed, Expanded Analysis (US & EU)
    • Introduction
      • Overview
      • Methodology
      • Rationale for Treatment Drivers and Goals Selection
        • Efficacy
        • Convenience of Administration
      • Rationale for Drug Selection
        • Products for Peripheral Arterial Disease
    • Treatment Drivers and Goals
      • Key Findings: Attribute Importance
      • Relative Importance of Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Surveyed Cardiologists' Prescribing Decisions in PAD
      • Importance of Efficacy Attributes to Prescribing Decisions in PAD: United States
      • Importance of Efficacy Attributes to Prescribing Decisions in PAD: Europe
      • Importance of Convenience of Administration Attributes to Prescribing Decisions in PAD: United States
      • Importance of Convenience of Administration Attributes to Prescribing Decisions in PAD: Europe
      • Key Findings: Stated vs. Derived Importance
      • Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in PAD: United States
      • Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in PAD: Europe
    • Product Performance Against Treatment Drivers and Goals
      • Key Findings
      • Overall Performance of Key Therapies for PAD: United States
      • Overall Performance of Key Therapies for PAD: Europe
      • Mean Overall Performance of Key Therapies for PAD: United States and Europe
      • Relative Performance of Key Therapies for PAD Across Select Efficacy Attributes: United States
      • Relative Performance of Key Therapies for PAD Across Select Efficacy Attributes: Europe
      • Relative Performance of Key Therapies for PAD Across Select Convenience of Administration Attributes: United States
      • Relative Performance of Key Therapies for PAD Across Select Convenience of Administration Attributes: Europe
    • Assessment of Unmet Need
      • Key Findings: Unmet Need in PAD
      • Surveyed Cardiologists’ Satisfaction with the Performance of Key Therapies for PAD on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
      • Surveyed Cardiologists’ Satisfaction with the Performance of Key Therapies for PAD on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: Europe
      • Surveyed Cardiologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in PAD: United States
      • Surveyed Cardiologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in PAD: Europe
      • Surveyed Cardiologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in PAD: United States
      • Surveyed Cardiologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in PAD: Europe
      • Key Findings: Unmet Need in PAD and Related Indications
      • Surveyed Cardiologists' Ascribed Level of Unmet Need in PAD and Related Indications: United States
      • Surveyed Cardiologists' Ascribed Level of Unmet Need in PAD and Related Indications: Europe
    • Opportunity Analysis
      • Areas of Opportunity in the Peripheral Arterial Disease Market and Emerging Therapy Insights
        • Opportunity: A Disease-Modifying Therapy
        • Opportunity: A Novel Agent Offering a Proven Reduction in Major Adverse Cardiovascular Events and All-Cause Mortality Rate
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
        • Attributes and Attribute Levels
      • Attribute Importance and Part-Worth Utilities
        • PAD Target Product Profile: Attribute Importance
        • Relative Risk Reduction in Major Adverse Cardiovascular Events
        • Relative Risk Reduction in All-Cause Mortality Rate
        • Relative Risk Reduction in Major Adverse Limb Events
        • Improvement in Rutherford Category
        • Mean Improvement in Maximal Walking Distance (in Meters)
        • Dosing Burden (Route of Administration and Frequency)
        • Average Price per Day
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Peripheral Arterial Disease Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 1
        • Peripheral Arterial Disease Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 1
        • Peripheral Arterial Disease Market Simulations: Target Product Profiles Included in Scenario 1
        • Peripheral Arterial Disease Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 2
        • Peripheral Arterial Disease Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 2
        • Peripheral Arterial Disease Market Simulations: Target Product Profiles Included in Scenario 2
    • Appendix
      • Key Abbreviations
      • Bibliography

Author(s): Pallavi Malik, M.Sc.

Pallavi Malik is a business insights analyst in the Cardiovascular, Metabolic and Renal disorders team at Decision Resources Group.

She obtained an M.Sc. degree with specializations in Biotechnology, and a Bachelor's degree in Science from the Panjab University, Chandigarh, India. Prior to joining DRG, she has worked as a Senior Business Analyst at the research firm Evalueserve. Her role involved in-depth scientific secondary research, and competitive intelligence across multiple domains (such as oncology, ophthalmology and CVD) including pipeline analysis, clinical trials assessment, disease landscaping, product and company profiling, competitor benchmarking, and opportunity assessment.

 


Related Reports

Peripheral Arterial Disease - Landscape And Forecast - Disease Landscape & Forecast

Peripheral arterial disease (PAD) is a common manifestation of systemic atherosclerosis affecting the arteries in the lower extremities. This condition is considered a major marker for systemic isc...

View Details

Peripheral Arterial Disease | Disease Landscape and Forecast | G7 | 2020

Peripheral arterial disease (PAD) is a common manifestation of systemic atherosclerosis affecting the arteries in the lower extremities. This condition is considered a major marker for systemic isc...

View Details

Peripheral Arterial Disease - Epidemiology - Mature Markets

DRG Epidemiology’s coverage of peripheral arterial disease (PAD) comprises epidemiological estim...

View Details

Peripheral Arterial Disease - Epidemiology - Emerging Markets

DRG Epidemiology’s coverage of peripheral arterial disease (PAD) comprises epidemiological estim...

View Details